20240208171546.png)
Memorial Sloan Kettering Cancer Center (MSK) has been recognized by the American College of Surgeons (ACS) for its commitment to providing optimal surgical care for children and adolescents.
Memorial Sloan Kettering Cancer Center Names Lawrence Schwartz, MD, New Chair of the Department of Radiology
20240208171546.png&width=400&height=400)
Stigma can have profound and lasting effects, and studies have shown that people living with lung cancer may encounter challenges in receiving the support they need from their social network and healthcare providers. Memorial Sloan Kettering Cancer Center (MSK) is committed to helping eliminate the stigmas associated with a lung cancer diagnosis and is working to raise awareness in collaboration with other national organizations.
Memorial Sloan Kettering Cancer Center (MSK) announced today that the U.S. Food and Drug Administration (FDA) has approved the oral MEK inhibitor drug cobimetinib (Cotellic®) for the treatment of adult patients with the family of blood diseases known as histiocytic neoplasms (HN). These diseases include Erdheim-Chester disease, Rosai-Dorfman disease, and Langerhans cell histiocytosis. Cobimetinib is an oral inhibitor of MEK1 and MEK2, currently approved to treat melanoma.
Memorial Sloan Kettering Cancer Center (MSK) today announced it has received a new grant from the National Cancer institute (NCI), part of the National Institutes of Health, under the umbrella of the Cancer Moonshot, to create the MATCHES (Making Telehealth Delivery of Cancer Care at Home Effective and Safe) Telehealth Research Center at MSK, a first of its kind.
Memorial Sloan Kettering Cancer Center (MSK) has been recognized as the number two hospital for cancer care in the nation by U.S. News & World Report in its annual Best Hospitals listing. Since these prestigious rankings were established more than 30 years ago, MSK has consistently ranked among the top two cancer hospitals in the country.
Memorial Sloan Kettering Cancer Center (MSK) today announced that Selwyn M. Vickers, MD, FACS, an internationally recognized pancreatic cancer surgeon and researcher, a pioneer in cancer health disparities research, and an academic medical leader, has been selected to serve as its next President and Chief Executive Officer.
Memorial Sloan Kettering Cancer Center (MSK) and the Robbins Family Foundation are proud to announce today that 13 distinguished MSK nurses and one nursing team were recognized with the 2022 Robbins Family Award for Nursing Excellence. During National Nurses Week (May 6 – 12), MSK recognizes outstanding nurses for exemplary service.
Memorial Sloan Kettering Cancer Center (MSK) today announced the establishment of The Starr Foundation Program for Discovery Science, a pioneering new initiative made possible by a generous $50 million gift from The Starr Foundation.
Memorial Sloan Kettering Cancer Center (MSK) is proud to announce that Fumiko Chino, MD; Craig B. Thompson, MD; and Jedd D. Wolchok, MD, PhD, FASCO, have been honored by the American Society of Clinical Oncology (ASCO) and Conquer Cancer, the ASCO Foundation, with three prestigious awards. These special awards, including the inaugural Excellence in Equity Award, the Science of Oncology Award, and the David Karnofsky Award, are awarded to researchers and global oncology leaders who have reshaped cancer care around the world and are among the highest honors bestowed by ASCO. Dr. Chino, Dr. Thompson, and Dr. Wolchok will be presented with the awards at the 2022 ASCO Annual Meeting in Chicago on June 3–7, 2022.
Five Memorial Sloan Kettering (MSK) faculty are among the 33 international scientific leaders elected today to the prestigious Fellows of the American Association for Cancer Research (AACR) Academy class of 2022.
Today, Craig B. Thompson announced his intention to step down as President and Chief Executive Officer of Memorial Sloan Kettering Cancer Center (MSK) and has asked the Boards of Trustees and Governing Trustees to begin a search for his successor. Thompson will continue in his role until the Board identifies his successor.
A new study from Memorial Sloan Kettering Cancer Center (MSK) provides important insights into cancer metastasis.
Memorial Sloan Kettering Cancer Center (MSK) today announced the creation of The Marie-Josée and Henry R. Kravis Cancer Ecosystems Project to spur the next revolution of preclinical research, discovery, and treatment. The new initiative, made possible by a generous $100 million gift from The Marie-Josée and Henry R. Kravis Foundation, will bring together teams of researchers from across the institution to explore the many interconnected elements that contribute to the relapse of cancer — the key driver of cancer deaths — guided by a holistic, strategic vision.
.jpg&width=400&height=400)
Memorial Sloan Kettering Cancer Center (MSK) today announced that Rémy Evard has joined as its new Chief Digital Officer and Head of Technology. In this role, Evard will be responsible for the overall design and execution of the organization’s digital strategy.
Launched with a $100 million commitment, the initiative will focus on the most impactful early-stage, translational cancer research.
Saad Usmani, MD, has been named Chief of the Myeloma Service at Memorial Sloan Kettering Cancer Center (MSK). He joins MSK from the Levine Cancer Center in North Carolina and succeeds C. Ola Landgren, MD, PhD, who previously served in this role for six years.
Memorial Sloan Kettering Cancer Center (MSK) today announced a generous $50 million gift from Mike and Maria Repole and the Nonna’s Garden Foundation to establish The Nonna’s Garden Foundation Initiative for Cancer Care and Research at MSK.
Memorial Sloan Kettering Cancer Center (MSK) is proud to announce three innovative investigators as the recipients of this year’s Paul Marks Prize for Cancer Research.
A new study from Memorial Sloan Kettering Cancer Center found that high-dose radiation therapy administered alongside systemic therapy in patients with metastatic non-small cell lung cancer can help extend progression free survival. This is the first and largest randomized clinical trial ever to study the use of stereotactic body radiation therapy (SBRT) in treating oligoprogressive metastatic lung and breast cancers. These findings will be presented during this year’s American Society for Radiation Oncology (ASTRO) meeting in Chicago.
RSS
Medicine keyboard_arrow_right
Sciencekeyboard_arrow_right
Life keyboard_arrow_right
Business keyboard_arrow_right
Journal News keyboard_arrow_right
By Location keyboard_arrow_right
Meetings, Grants, and Events keyboard_arrow_right